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To the Editor: Methicillin-resistant Staphylococcus 
aureus (MRSA) is a versatile pathogen capable of causing 
a wide variety of human diseases. Increased frequency of 
S. aureus infections imposes a high and increasing burden 
on healthcare resources. In many countries, MRSA infec-
tions in hospitals are common. Data from the National 
Nosocomial Infections Surveillance system suggest that, 
in the United States, incidence of nosocomial MRSA in-
fections is steadily increasing and that these infections ac-
count for >60% of intensive care unit admissions (1,2). S. 
aureus has developed resistance to several antimicrobial 
drugs, including second- and third-line drugs. Only a few 
drugs, such as vancomycin (a glycopeptide), daptomycin (a 
lipopeptide), and linezolid (an oxazolidinone), have been 
approved for the treatment of serious infections caused by 
MRSA. Another drug, tigecycline (a glycylcycline), has 
shown good activity against MRSA strains in vitro (3). The 
epidemiology of MRSA is constantly changing, which re-
sults in variation in its drug-resistance patterns throughout 
regions and countries (4). Therefore, to support clinicians 
in preventing and treating infection, epidemiologic surveil-
lance is essential. We report resistance patterns of S. aureus 
collected over 2 years (December 2013–November 2015) 
from blood samples of patients admitted to 1 hospital in 
Odisha, eastern India.
A total of 47 S. aureus isolates were collected; only 1 
isolate per patient was included in the study. Susceptibility 
of the isolates was tested against antimicrobial agents ac-
cording to the Clinical and Laboratory Standards Institute 
broth microdilution procedure and interpretation criteria 
(http://clsi.org/). MICs for the isolates were confirmed by 
using a Vitek 2 Compact automated system (bioMérieux, 
Marcy l’Étoile, France). S. aureus ATCC 25923 was used 
as a control strain. S. aureus identification was confirmed 
by using a Vitek 2 system, by hemolytic activity on blood 
agar, and by positive catalase activity test results. Clinical 
MRSA isolates were analyzed by using PCR with specific 
primers: mecA (5), cfr (6), and VanA (7).
 Among the 47 S. aureus isolates, 28 (60%) were re-
sistant to oxacillin (MICs 4–64 mg/L) and cefoxitin (MICs 
8–64 mg/L). All MRSA isolates were able to grow in selec-
tive medium containing either aztreonam (75 mg/L) or co-
listin (10 mg/L). Screening of MRSA isolates showed that 
2 isolates were highly resistant to vancomycin (MIC >100 
mg/L) (Figure). Further screening showed that both van-
comycin-resistant isolates were also resistant to linezolid 
(MIC >100 mg/L) (Figure). PCR amplification of both iso-
lates indicated presence of all 3 genetic determinants: mecA 
(methicillin resistance), cfr (linzolid resistance), and VanA 
(vancomycin resistance). Among the 3 isolates that showed 
resistance to tigecycline (MIC >50 mg/L), 1 isolate was sus-
ceptible to vanocmycin and linezolid (Figure). Unlike previ-
ously reported isolates, these 2 MRSA isolates showed resis-
tant phenotypes to linezolid, tigecycline, and vancomycin.
MICs observed in this study were higher than those 
previously reported. Vancomycin-resistant S. aureus has 
been identified in many other countries. Most linezolid-
resistant S. aureus has been isolated from patients in North 
America and Europe (8). The tigecycline-resistant S. au-
reus isolate (MIC >0.5 mg/L) reported from Brazil was also 
susceptible to linezolid, teicoplanin, and vancomycin (9).
This study indicates the emergence of multidrug-resis-
tant S. aureus with co-resistance to methicillin, vancomycin, 
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Figure. Distribution of various resistance types of Staphylococcus 
aureus isolates collected in eastern India, 2013–2015. LRSA, 
linezolid-resistant S. aureus; MRSA, methicillin-resistant S. 
aureus; MSSA, methicillin-sensitive S .aureus; TRSA, tigecycline-
resistant S. aureus; VRSA, vancomycin-resistant S. aureus.
linezolid, and tigecycline. Although the clinical signifi-
cance of these findings is unknown, the decline in drug ef-
fectiveness against S. aureus infections represents a loom-
ing threat to patient health and highlights the possibility of 
a return to illness and death rates similar to those before 
antimicrobial drugs were available.
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To the Editor: Colistin belongs to the last line of 
bactericidal antimicrobial drugs active against multidrug-
resistant gram-negative bacteria such as carbapenemase-
producing Enterobacteriaceae and carbapenem-resistant 
Acinetobacter baumannii. Consequently, the discovery 
of the plasmid-mediated colistin-resistant gene mcr-1 in 
Escherichia coli (1) raises concern in the medical commu-
nity because colistin might be useless in treating infections 
caused by mcr-1–carrying Enterobacteriaceae.
During December 8, 2015–January 8, 2016, we con-
ducted prospective laboratory surveillance of mcr-1–carrying 
Enterobacteriaceae and Acinetobacter species in a university-
affiliated tertiary hospital serving a population of ≈0.53 mil-
lion in Hong Kong, China. Clinical specimens were processed 
by using standard operating procedures for different specimen 
types (2). All Enterobacteriaceae and Acinetobacter spp. iso-
lates were plated onto MH1 agar, which is Mueller-Hinton 
agar (BD Diagnostics, Sparks, MD, USA), supplemented 
with 1 µg/mL colistin sulfate (Sigma-Aldrich, St. Louis, MO, 
USA) for overnight incubation at 37°C in air. Intrinsically co-
listin-resistant organisms, including Proteus spp., Providencia 
spp., Serratia spp., and Morganella morganii, were exclud-
ed. E. coli ATCC 25922 was used as a negative control. We 
screened bacteria that grew on MHC1 for mcr-1 by real-time 
PCR that used specific primers MCR1_22697_F1 (5′-CACT-
TATGGCACGGTCTATGA-3′) and MCR1_22810_R1 
(5′-CCCAAACCAATGATACGCAT-3′) and the hydro-
lysis probe MCR1_22763_Pb1 (FAM-TGGTCTCGG/ 
ZEN/CTTGGTCGGTCTGTAGGGC-3IABkFQ) (Inte-
grated DNA Technologies, Coralville, IA, USA). The com-
plete mcr-1 gene found in PCR-positive isolates was ampli-
fied and sequenced by specific primers. The colistin MIC of 
positive isolates was measured by using Etest strips (Bio-
Mérieux, Marcy l’Etoile, France). Susceptibility to other 
antimicrobial drugs was determined by using the Kirby-
Bauer disk diffusion method, according to Clinical and Labo-
ratory Standards Institute guidelines (3). We retrieved clinical 
details of patients whose sample had mcr-1–carrying Entero-
bacteriaceae from the hospital clinical management system.
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